Abstract

Manual microscopic inspection of fixed and stained blood smears has remained the gold standard for Plasmodium parasitemia analysis for over a century. Unfortunately, smear preparation consumes time and reagents, while manual microscopy is skill-dependent and labor-intensive. Here, we demonstrate that deep learning enables both life stage classification and accurate parasitemia quantification of ordinary brightfield microscopy images of live, unstained red blood cells. We tested our method using both a standard light microscope equipped with visible and near-ultraviolet (UV) illumination, and a custom-built microscope employing deep-UV illumination. While using deep-UV light achieved an overall four-category classification of Plasmodium falciparum blood stages of greater than 99% and a recall of 89.8% for ring-stage parasites, imaging with near-UV light on a standard microscope resulted in 96.8% overall accuracy and over 90% recall for ring-stage parasites. Both imaging systems were tested extrinsically by parasitemia titration, revealing superior performance over manually-scored Giemsa-stained smears, and a limit of detection below 0.1%. Our results establish that label-free parasitemia analysis of live cells is possible in a biomedical laboratory setting without the need for complex optical instrumentation. We anticipate future extensions of this work could enable label-free clinical diagnostic measurements, one day eliminating the need for conventional blood smear analysis.

Highlights

  • Malaria is among the deadliest infectious diseases in human history

  • We show that our machine classifiers are more accurate over a larger range of parasitemia than human technicians scoring Giemsa-stained smears prepared from the same samples

  • Of the five Plasmodium species that cause illness in humans, P. falciparum accounts for 99% of cases in Africa, and 94% of all malaria deaths [1]

Read more

Summary

Introduction

Of the five Plasmodium species that cause illness in humans, P. falciparum accounts for 99% of cases in Africa, and 94% of all malaria deaths [1]. P. falciparum possesses a well-evolved ability to evade host immunity in both the Anopheles vector and the human host through various allelic adaptations and antigenic variation [6]. These factors put considerable pressure on the therapeutic development process to continuously identify and target orthogonal mechanisms of action

Methods
Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call